Protagenic Therapeutics (PTIX) Competitors $0.27 +0.01 (+2.12%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$0.26 0.00 (-0.94%) As of 02/21/2025 05:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrends PTIX vs. HOTH, EVOK, RDHL, CELZ, EDSA, BLRX, ORGS, PRPH, ALZN, and OMGAShould you be buying Protagenic Therapeutics stock or one of its competitors? The main competitors of Protagenic Therapeutics include Hoth Therapeutics (HOTH), Evoke Pharma (EVOK), RedHill Biopharma (RDHL), Creative Medical Technology (CELZ), Edesa Biotech (EDSA), BioLineRx (BLRX), Orgenesis (ORGS), ProPhase Labs (PRPH), Alzamend Neuro (ALZN), and Omega Therapeutics (OMGA). These companies are all part of the "pharmaceutical products" industry. Protagenic Therapeutics vs. Hoth Therapeutics Evoke Pharma RedHill Biopharma Creative Medical Technology Edesa Biotech BioLineRx Orgenesis ProPhase Labs Alzamend Neuro Omega Therapeutics Hoth Therapeutics (NASDAQ:HOTH) and Protagenic Therapeutics (NASDAQ:PTIX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, earnings, risk, media sentiment, valuation, community ranking, analyst recommendations and institutional ownership. Does the MarketBeat Community prefer HOTH or PTIX? Hoth Therapeutics received 74 more outperform votes than Protagenic Therapeutics when rated by MarketBeat users. CompanyUnderperformOutperformHoth TherapeuticsOutperform Votes7466.07% Underperform Votes3833.93% Protagenic TherapeuticsN/AN/A Does the media refer more to HOTH or PTIX? In the previous week, Hoth Therapeutics' average media sentiment score of 0.00 equaled Protagenic Therapeutics'average media sentiment score. Company Overall Sentiment Hoth Therapeutics Neutral Protagenic Therapeutics Neutral Is HOTH or PTIX more profitable? Hoth Therapeutics' return on equity of -89.68% beat Protagenic Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Hoth TherapeuticsN/A -89.68% -82.61% Protagenic Therapeutics N/A -308.97%-228.73% Do insiders & institutionals believe in HOTH or PTIX? 7.1% of Hoth Therapeutics shares are owned by institutional investors. Comparatively, 8.0% of Protagenic Therapeutics shares are owned by institutional investors. 10.6% of Hoth Therapeutics shares are owned by company insiders. Comparatively, 35.0% of Protagenic Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Which has preferable valuation & earnings, HOTH or PTIX? Hoth Therapeutics is trading at a lower price-to-earnings ratio than Protagenic Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHoth TherapeuticsN/AN/A-$7.84M-$1.32-0.80Protagenic TherapeuticsN/AN/A-$5M-$1.27-0.21 Which has more risk & volatility, HOTH or PTIX? Hoth Therapeutics has a beta of 0.8, suggesting that its stock price is 20% less volatile than the S&P 500. Comparatively, Protagenic Therapeutics has a beta of 0.25, suggesting that its stock price is 75% less volatile than the S&P 500. Do analysts prefer HOTH or PTIX? Hoth Therapeutics currently has a consensus price target of $4.00, indicating a potential upside of 277.36%. Given Hoth Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Hoth Therapeutics is more favorable than Protagenic Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Hoth Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25Protagenic Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryHoth Therapeutics beats Protagenic Therapeutics on 8 of the 12 factors compared between the two stocks. Get Protagenic Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PTIX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PTIX vs. The Competition Export to ExcelMetricProtagenic TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.88M$7.07B$5.85B$9.15BDividend YieldN/A2.76%4.76%3.85%P/E RatioN/A2.5616.5114.19Price / SalesN/A304.55450.0276.60Price / CashN/A65.6738.0134.95Price / Book0.326.717.644.63Net Income-$5M$138.11M$3.18B$245.69M7 Day Performance-0.93%-2.54%-1.95%-2.68%1 Month Performance-35.01%-2.00%-0.23%-2.16%1 Year Performance-72.91%-5.04%16.69%12.90% Protagenic Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PTIXProtagenic TherapeuticsN/A$0.27+2.1%N/A-73.7%$1.88MN/A0.002HOTHHoth Therapeutics2.8251 of 5 stars$1.08-6.9%$4.00+270.4%-21.5%$7.45MN/A-0.824Gap DownEVOKEvoke Pharma0.0994 of 5 stars$4.84+0.6%N/A-40.8%$7.19M$8.62M-0.444Gap DownRDHLRedHill Biopharma0.5846 of 5 stars$5.59+1.6%N/A-98.6%$7.16M$6.53M0.00210Positive NewsCELZCreative Medical Technology0.902 of 5 stars$3.98-5.9%N/A+28.0%$6.96M$11,000.00-1.055Gap DownEDSAEdesa Biotech2.6731 of 5 stars$1.94+1.3%$21.00+984.7%-53.9%$6.72MN/A-1.0020Earnings ReportBLRXBioLineRx2.487 of 5 stars$3.34+0.3%$360.00+10,678.4%-92.2%$6.68M$4.80M-0.3840ORGSOrgenesisN/A$1.38+16.9%N/AN/A$6.62M$530,000.000.00150Gap UpPRPHProPhase Labs1.8803 of 5 stars$0.26+0.7%$11.00+4,090.5%-89.2%$6.27M$44.38M-0.21130News CoverageALZNAlzamend Neuro2.6127 of 5 stars$1.13-1.3%$32.00+2,744.4%-88.9%$6.11MN/A0.004Gap UpOMGAOmega Therapeutics2.6628 of 5 stars$0.11-6.9%$9.20+8,418.5%-95.6%$5.98M$3.09M-0.08120Gap DownHigh Trading Volume Related Companies and Tools Related Companies Hoth Therapeutics Alternatives Evoke Pharma Alternatives RedHill Biopharma Alternatives Creative Medical Technology Alternatives Edesa Biotech Alternatives BioLineRx Alternatives Orgenesis Alternatives ProPhase Labs Alternatives Alzamend Neuro Alternatives Omega Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:PTIX) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredNvidia’s Next Big Move Comes on Feb. 26Nvidia isn't the only company that benefits greatly from these earnings calls. That's because a handful of ...Weiss Ratings | SponsoredHow to trade Executive Order 14154Trump’s pen must be running out of ink… Since he returned to office he’s signed more than 50 Executive Orde...Porter & Company | SponsoredMajor AI announcement for 2025BIG NEWS: “Market Wizard” Larry Benedict Releases a Whole New Way to Trade AI StocksBrownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Protagenic Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Protagenic Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
